The impact of change in serum C‐reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma

Abstract

A decrease of CRP and pretreatment CRP levels show promise as a novel predictive factor for anti-tumour effects in patients treated with molecular targeted therapy.